(19)
(11)EP 3 587 447 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
13.05.2020 Bulletin 2020/20

(43)Date of publication A2:
01.01.2020 Bulletin 2020/01

(21)Application number: 19186022.0

(22)Date of filing:  27.01.2012
(51)Int. Cl.: 
C07K 16/00  (2006.01)
C12N 15/13  (2006.01)
C07K 16/18  (2006.01)
A61P 35/00  (2006.01)
A61P 43/00  (2006.01)
A61K 39/395  (2006.01)
C40B 40/10  (2006.01)
C07K 16/40  (2006.01)
A61P 37/00  (2006.01)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 28.01.2011 US 201161437174 P

(62)Application number of the earlier application in accordance with Art. 76 EPC:
12738867.6 / 2668206

(71)Applicant: National Research Council of Canada
Ottawa, Ontario K1A 0R6 (CA)

(72)Inventors:
  • Kim, Dae Young
    Ottawa, Ontario K4A 5A2 (CA)
  • Tanha, Jamshid
    Ottawa, Ontario K1C 7M6 (CA)

(74)Representative: Fleuchaus, Andrea et al
Fleuchaus & Gallo Partnerschaft mbB Patentanwälte Steinerstraße 15/Haus A
81369 München
81369 München (DE)

  


(54)ENGINEERING OF IMMUNOGLOBULIN DOMAINS


(57) The present invention provides a single domain antibody (sdAb) scaffold comprising one or more than one non-canonical disulfide bond in the framework region (FR). The one or more than one non-canonical disulfide bond may be formed between cysteines introduced by mutations in FR2 and FR3. In the case where the sdAb scaffold is a VH, the Cys may be introduced at any one of positions 47-49 and any one of positions 67-71, based on Kabat numbering; in one example, the Cys may be introduced at positions 49 and 69, based on Kabat numbering. In the case where the sdAb scaffold is a VL, the Cys residues may be introduced at any one of positions 46-49 and any one of positions 62-66, based on Kabat numbering; in one example, the Cys residues may be introduced at positions 48 and 64, based on Kabat numbering.